Webber J A, Yoshida T
Rev Infect Dis. 1982 Nov-Dec;4 Suppl:S496-500. doi: 10.1093/clinids/4.supplement_3.s496.
Moxalactam is the first member of a new class of beta-lactam antibiotics to be evaluated clinically. Although structurally related to cephalosporins, moxalactam has an oxygen atom where the cephalosporin nucleus has a sulfur atom. The substitution of oxygen for sulfur in moxalactam provides it with greater antibacterial activity than that of its cephalosporin analog. Moxalactam has three other structural elements that affect biologic activity: the methyltetrazolethio moiety, which maximizes in vitro activity; the 7-alpha-methoxy substituent, which confers beta-lactamase stability; and the p-hydroxyphenylmalonyl group, which positively influences not only beta-lactamase stability and the antibacterial spectrum of moxalactam, but also its pharmacokinetics, and leads to a long half-life without high serum binding.
拉氧头孢是一类新型β-内酰胺抗生素中首个进入临床评估的药物。尽管拉氧头孢在结构上与头孢菌素相关,但在头孢菌素核含有硫原子的位置,拉氧头孢含有一个氧原子。拉氧头孢中氧取代硫使其具有比其头孢菌素类似物更强的抗菌活性。拉氧头孢还有其他三个影响生物活性的结构元件:使体外活性最大化的甲基四氮唑硫基团;赋予β-内酰胺酶稳定性的7-α-甲氧基取代基;以及对β-内酰胺酶稳定性、拉氧头孢的抗菌谱、药代动力学均有积极影响且能导致长半衰期而无高血清结合率的对羟基苯基丙二酰基。